Poster Presentations, Poster Session Hepatitis B S75 regulated by wild and mutant HBx, demonstrated a lower level in the LO2/HBx-d382 cell. Further characterization of miR-338 3p revealed that it negatively regulated cellular profileration. Cell cycle analysis showed that miR-338 3p induced cell cycle arrest at the G1/S phase. A dualluciferase reporter assay demonstrated that the 3 UTR of CyclinD1 were directly bound to miR-338 3p and western blotting analysis further indicated that miR-338 3p downregulated the expression of CyclinD1. Conclusion: This study demonstrates that HBx can influence cellular miRNA expression. The deregulation of the expression of miR-338 3p by HBx may represent a potential novel pathway which HBx acts to deregulate cell proliferation leading to hepatocarcinogenesis. .874 copies log 10 /ml, 6.010±2.016 copies log 10 /ml and 5.664±1.548 copies log 10 /ml respectively (P = 0.408). Serum HBV DNA level in 42 patients with HBsAg (~±), 79 patients with (+~++) and 19 patients with (+++~++++) was 5.886±1.997 copies log 10 /ml, 5.968±2.020 copies log 10 /ml and 5.634±1.551 copies log 10 /ml respectively (P = 0.800). Conclusions: The expression of HBsAg, HBcAg in the liver does not correlate with serum HBV DNA level. Results: The serum HBV DNA loads in HBeAg-positive group with inflammation grades G 0 1 (6 patients), G 2 (74 patients) and G 3 4 (25 patients) were 5.580±1.098 copies log 10 /ml, 6.520±2.004 copies log 10 /ml and 6.950±1.467 copies log 10 /ml respectively. There was no significant difference in patients of three inflammation grades (P = 0.250). The serum HBV DNA loads in HBeAg-positive group with liver tissues fibrosis stages of S 0 1 (23 patients), S 2 (56 patients), S 3 4 (26 patients) were 6.599±1.832 copies log 10 /ml, 6.559±2.012 copies log 10 /ml, 6.562±1.601 copies log 10 /ml respectively, the difference was not significant (P = 0.996). The serum HBV DNA loads in HBeAg-negative group with inflammation grades G 0 1 (8 patients), G 2 (17 patients) and G 3 4 (28 patients) were 2.132±1.875 copies log 10 /ml, 4.745±2.250 copies log 10 /ml and 5.581±2.305 copies log 10 /ml respectively. The serum HBV DNA level in patients with G 2 and G 3 4 inflammation grades was significant higher than in patients with G 0 1 inflammation grades (P = 0.001). The serum HBV DNA loads in HBeAg-negative group with liver tissues fibrosis stages of S 0 1 (10 patients), S 2 (45 patients), S 3 4 (18 patients) were 2.689±3.225 copies log 10 /ml, 5.127±1.833 copies log 10 /ml, 5.375±2.410 copies log 10 /ml respectively. The serum HBV DNA level in patients with fibrosis stages of S 2 and S 3 4 was significant higher than in patients with fibrosis stages of S 0 1 (P = 0.005). Conclusions: The serum HBV DNA level does not correlate with the inflammation grades and fibrosis stages of liver tissues in HBeAg-positive patients. The serum HBV DNA loads display a positive correlation with the inflammation grades and fibrosis stages of liver tissues in HBeAg-negative patients.
Objective: The aim of this study was to investigate the relationship between HBsAg, HBcAg expression and serum HBV DNA level. Methods: The expression of HBsAg, HBcAg in the livers of 140 patients with chronic hepatitis B was detected by immunohistochemistry. And the level of serum hepatitis B virus DNA (HBV DNA) was tested. Statistical significance was assessed using One-Way analysis of variance (ANOVA). Results: Serum HBV DNA level in 13 patients with HBsAg (~±), 108 patients with (+~++) and 19 patients with (+++~++++) was 5.313±1.874 copies log 10 /ml, 6.010±2.016 copies log 10 /ml and 5.664±1.548 copies log 10 /ml respectively (P = 0.408). Serum HBV DNA level in 42 patients with HBsAg (~±), 79 patients with (+~++) and 19 patients with (+++~++++) was 5.886±1.997 copies log 10 /ml, 5.968±2.020 copies log 10 /ml and 5.634±1.551 copies log 10 /ml respectively (P = 0.800). Objective: To investigate the relationship between serum HBV DNA loads and liver pathological changes in the patients with chronic hepatitis B. Methods: The relationship among HBV DNA loads, live histological inflammation grades and fibrosis stages of 158 cases was analyzed. Results: The serum HBV DNA loads in HBeAg-positive group with inflammation grades G 0 1 (6 patients), G 2 (74 patients) and G 3 4 (25 patients) were 5.580±1.098 copies log 10 /ml, 6.520±2.004 copies log 10 /ml and 6.950±1.467 copies log 10 /ml respectively. There was no significant difference in patients of three inflammation grades (P = 0.250). The serum HBV DNA loads in HBeAg-positive group with liver tissues fibrosis stages of S 0 1 (23 patients), S 2 (56 patients), S 3 4 (26 patients) were 6.599±1.832 copies log 10 /ml, 6.559±2.012 copies log 10 /ml, 6.562±1.601 copies log 10 /ml respectively, the difference was not significant (P = 0.996). The serum HBV DNA loads in HBeAg-negative group with inflammation grades G 0 1 (8 patients), G 2 (17 patients) and G 3 4 (28 patients) were 2.132±1.875 copies log 10 /ml, 4.745±2.250 copies log 10 /ml and 5.581±2.305 copies log 10 /ml respectively. The serum HBV DNA level in patients with G 2 and G 3 4 inflammation grades was significant higher than in patients with G 0 1 inflammation grades (P = 0.001). The serum HBV DNA loads in HBeAg-negative group with liver tissues fibrosis stages of S 0 1 (10 patients), S 2 (45 patients), S 3 4 (18 patients) were 2.689±3.225 copies log 10 /ml, 5.127±1.833 copies log 10 /ml, 5.375±2.410 copies log 10 /ml respectively. The serum HBV DNA level in patients with fibrosis stages of S 2 and S 3 4 was significant higher than in patients with fibrosis stages of S 0 1 (P = 0.005). Conclusions: The serum HBV DNA level does not correlate with the inflammation grades and fibrosis stages of liver tissues in HBeAg-positive patients. The serum HBV DNA loads display a positive correlation with the inflammation grades and fibrosis stages of liver tissues in HBeAg-negative patients.
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